The Anti-Tumor Effect of Boron Neutron Capture Therapy in Glioblastoma Subcutaneous Xenograft Model Using the Proton Linear Accelerator-Based BNCT System in Korea

Boron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells and is being actively researched and developed around the world. In Korea, development of the proton linear accelerator-based BNCT system has completed development, and its anti-cancer effect in the U-87...

Full description

Saved in:
Bibliographic Details
Published in:Life (Basel, Switzerland) Switzerland), 2022-08, Vol.12 (8), p.1264
Main Authors: Seo, Il Hyeok, Lee, Jeongwoo, Na, Dasom, Kyung, Hyunhye, Yang, Jieun, Lee, Sangbong, Jeon, Sang June, Choi, Jae Won, Lee, Kyu Young, Yi, Jungyu, Han, Jaehwan, Yoo, Mooyoung, Kim, Se Hyun
Format: Article
Language:English
Subjects:
Anticancer properties
Blood levels
BNCT
Boron
BPA
Brain cancer
Cancer
Cancer therapies
Cell culture
Cell survival
Cell viability
Clinical trials
Evaluation
Experiments
Fractions
Generators
Glioblastoma
Irradiation
Korea
linear accelerator
Neutron irradiation
Neutrons
Nuclear capture
Penicillin
Protons
Radiation
Radiation dosage
Radiation therapy
Tumors
Xenografts
Xenotransplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Boron neutron capture therapy (BNCT) is a radiation therapy that selectively kills cancer cells and is being actively researched and developed around the world. In Korea, development of the proton linear accelerator-based BNCT system has completed development, and its anti-cancer effect in the U-87 MG subcutaneous xenograft model has been evaluated. To evaluate the efficacy of BNCT, we measured B-enriched boronophenylalanine (BPA) uptake in U-87 MG, FaDu, and SAS cells and evaluated cell viability by clonogenic assays. In addition, the boron concentration in the tumor, blood, and skin on the U-87 MG xenograft model was measured, and the tumor volume was measured for 4 weeks after BNCT. In vitro, the intracellular boron concentration was highest in the order of SAS, FaDu, and U-87 MG, and cell survival fractions decreased depending on the BPA treatment concentration and neutron irradiation dose. In vivo, the tumor volume was significantly decreased in the BNCT group compared to the control group. This study confirmed the anti-cancer effect of BNCT in the U-87 MG subcutaneous xenograft model. It is expected that the proton linear accelerator-based BNCT system developed in Korea will be a new option for radiation therapy for cancer treatment.
ISSN:2075-1729
2075-1729
DOI:10.3390/life12081264